08:49 AM EDT, 06/24/2024 (MT Newswires) -- Alnylam Pharmaceuticals ( ALNY ) said Monday that vutrisiran, an investigational therapy for treating ATTR amyloidosis with cardiomyopathy, met its primary and secondary endpoints in the late-stage study.

Alnylam said the study showed a statistically significant reduction in the composite of all-cause mortality and recurrent cardiovascular events during the double-blind period in both the overall population and the monotherapy population.

The drugmaker said the study also showed statistically significant improvements across all secondary endpoints, including a 6-minute walk test, Kansas City Cardiomyopathy Questionnaire and New York Heart Association Class in patients treated with vutrisiran.

The company said it plans to proceed with global regulatory filings later this year, including filing a supplemental New Drug Application to the US Food and Drug Administration using a Priority Review Voucher.

Shares of the company were up than 37% in recent Monday premarket trading.

Price: 227.24, Change: +61.54, Percent Change: +37.14